NRX Nurexone Biologic Inc

NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a biopharmaceutical company developing exosome-based therapies for the multi-billion dollar regenerative medicinei market, is pleased to announce its participation in a series of prestigious conferences this October. These events will showcase the Company’s advancements in exosome therapy, reinforce its commitment to driving innovation in regenerative medicine, and increase visibility with major pharmaceutical companies.

In October, NurExone will sponsor and present at the World Orphan Drug Congress in Barcelona from October 22-25, 2024. This prominent event unites global leaders in orphan drug development and rare diseases with a focus on strategy, advocacy and partnerships. NurExone will highlight its cutting-edge work in exosome-based therapies aimed at regeneration of neurons in the central nervous system leading to recovery of motor function after acute spinal cord injuries. Notably, NurExone is one of a small number of companies to receive Orphan Drug Designation for acute spinal cord injury.ii

Additionally, Dr. Noa Avni, research and development director of NurExone, will present at the Precision EV Forum 2024 in Cambridge, UK, from October 22-23, 2024 (“EV” refers to “Extracellular Vesicles”). She will present in the session titled ‘Approaching Translational Challenges for Therapeutic EVs,’ addressing key hurdles in bringing EV-based therapies to clinical applications, presenting NurExone's unique technology and potential. Furthermore, NurExone will chair the ‘Plenary Session: Production of EVs Under GMP Conditions’, sharing its learnings and capabilities in transferring technology to scaled GMP-compliant EV production for therapeutic use.

Lastly, NurExone will be presenting at the Israeli Society of Gene and Cell Therapy's (ISGCT 2024) meeting in September in Israel. As gene and cell therapy gain momentum globally, NurExone is proud to participate alongside other leading Israeli researchers who are making significant contributions to advancements in stem cell research, genome editing, and T cell engineering.

As previously announced, NurExone’s Chief Executive Officer, Dr. Lior Shaltiel, will also speak at the Bioprocess International Conference in Boston, taking place from September 23-26, 2024. At this leading industry event, Dr. Shaltiel will present the Company’s groundbreaking ExoPTEN nanodrug, a potential treatment for acute spinal cord injuries and other central nervous system conditions, including glaucoma. This appearance highlights NurExone’s growing influence in the field of exosome-based therapies for clinical applications.

Dr. Shaltiel commented: “through our strategy of active engagement in prestigious industry conferences we aim to advance therapeutic exosomes and help address the critical challenges that currently exist in the development landscape for central nervous system diseases. These events provide invaluable opportunities to meet with industry peers, present the Company’s achievements and explore potential collaborations as we expand the therapeutic potential of ExoPTEN across additional indications. We are proud to share our progress and vision with the global scientific community.”

About NurExone

NurExone Biologic Inc. is a TSX Venture Exchange (“TSXV”) and OTCQB listed pharmaceutical company that is developing a platform for biologically-guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, was proven to recover motor function in 75% of laboratory rats when administered intranasally. ExoPTEN has been granted Orphan Drug Designation by the FDA. The NurExone platform technology is expected to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.

For more information, please contact:

Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: info@nurexone.com

Thesis Capital Inc.Investor Relations - CanadaPhone: +1 905-347-5569Email: IR@nurexone.com

Dr. Eva ReuterInvestor Relations - GermanyPhone: +49-69-1532-5857Email: e.reuter@dr-reuter.eu

Allele Capital PartnersInvestor Relations - USPhone: +1 978-857-5075Email: aeriksen@allelecapital.com

FORWARD-LOOKING STATEMENTS

This press release contains certain “forward-looking statements” that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the Company presenting at the upcoming conferences, the focus of the presentations and the intended outcome of the presentations; the presenters at the conferences; the Company’s ExoPTEN nanodrug being a potential treatment for acute spinal cord injuries and other central nerve system indications; the Company engaging with collaboration partners, industry leaders, researchers and innovators; and the NurExone platform technology offering novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications.

These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including the general business and economic conditions of the industries and countries in which we operate; the general market conditions; the ability to secure additional funding; partnerships having their intended impact on the Company and its business; patents safeguarding NurExone’s technology; the Company’s drug products having its intended benefits and effects; the Company making progress through new partnerships and technologies to move towards commercialization of their products; the Company’s intellectual property and technology being novel and inventive; the intellectual property having the intended impact on the Company and its business; exosomes becoming an ideal and natural choice for drug delivery; the Company making advancements in the manufacturing process of exosomes; exosomes holding immense promise for regenerative medicine; the Company’s production methods continuing to be reliable; the Company will have flexibility in optimizing its exosome production method; exosomes will serve as an excellent, targeted system for drug delivery; the Company will pave the way to regenerative medicine treatments for a variety of clinical indications by the Company and with future collaboration partners; the Company will present at the upcoming conferences, focus the presentations on the subject matter indicated herein and the presentations will have their intended outcomes on the Company and its business; the Company’s ExoPTEN nanodrug being a potential treatment for acute spinal cord injuries and other central nerve system indications; the Company will engage with collaboration partners, industry leaders, researchers and innovators; and the NurExone platform technology offering novel solutions to drug companies.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to the Company’s early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; protection of the Company’s intellectual property; dependence on the Company’s strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the potential inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the potential inability to obtain adequate financing; the potential inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; the NurExone platform technology being unable to offer novel solutions to drug companies; risks that the Company’s intellectual property and technology won’t have the intended impact on the Company and/or its business; the Company’s inability to realize upon partnerships; risk that the exosomes will not become an ideal and/or natural choice for drug delivery; risk that the company will be unable to make advancements in the manufacturing process of exosomes; risk that exosomes will not be a viable option in regenerative medicine; risk that the Company’s production methods will become unreliable; risk that the Company will not have flexibility in optimizing its exosome production method; risk that exosomes will not serve as a targeted system for drug delivery; risk that the Company will be unable to pave the way to regenerative medicine treatments for a variety of clinical indications by the Company and/or with future collaboration partners; risk that the Company will be unable to present at the upcoming conferences, the subject matter of the presentations will change and/or the presentations will not have the intended outcome on the Company and/or its business; risk that the Company’s ExoPTEN nanodrug will not work as a potential treatment for acute spinal cord injuries and/or other central nerve system indications; risk that the Company will be unable to engage with collaboration partners, industry leaders, researchers and/or innovators at the conferences or at all; risk that the NurExone platform technology will be unable to offer novel solutions to drug companies interested in noninvasive targeted drug delivery for other indications; and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated March 30, 2023, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

______________________________i https://www.novaoneadvisor.com/report/us-regenerative-medicine-marketii https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm